Healthcare in United States
46 verified figures for United States, covering 39 indicators from 3 primary sources. Every figure links to the report it came from.
The short version
Key takeaways
- Novel active substance launches in United States stood at 53 in 2025 (IQVIA). IQVIA ↗
- Rural Health Transformation Program state investment in United States totalled 104 million USD as of 15 September 2026 (CMS). CMS ↗ T1 Official
- Aggregate revenue of patient organizations in United States totalled 62.5 billion USD in 2016–2020 (IQVIA). IQVIA ↗
- Medicare IPPS discharge volume in United States (top 100 DRGs) totalled 7,000,000 in 2011–2012 (CMS). CMS ↗ T1 Official
- Kindergarten vaccination coverage decline in United States came in at 0.1% in 2025–2026 (CDC). CDC ↗ T1 Official
- Drug overdose deaths in United States stood at 67,798 in 2025–2026 (CDC). CDC ↗ T1 Official
- Lung cancer screening rate among eligible program members in United States stood at 54% in 2024 (CDC). CDC ↗ T1 Official
- Net medicine spending growth rate in United States came in at 10.6% in 2025 (IQVIA). IQVIA ↗
- Average annual revenue of patient organizations in United States totalled 12.5 billion USD in 2016–2020 (IQVIA). IQVIA ↗
- IQVIA projects medicine spending growth forecast at list prices in United States (high) at 9% in 2026–2030. IQVIA ↗
The complete table
Healthcare data for United States
Every row links to its own page with the full source, verbatim quote and citation.
46 data points across 39 indicators. Each line shows the latest value; open a line for earlier periods and forecasts.
IndicatorPeriodValueSourceType
Aggregate revenue of patient organizations2016–202062.5 billion USDIQVIA2020actual→
Annual revenue growth rate of largest patient organizations2016–20205%IQVIA2020actual→
Average annual revenue of patient organizations2016–202012.5 billion USDIQVIA2020estimate→
Commercial insurance out-of-pocket cost growth20255%IQVIA2025actual→
Commercial insurance out-of-pocket cost growth (5-year)2021–202537%IQVIA2025actual→
Commercial insurance share of patient out-of-pocket costs202552%IQVIA2025actual→
Country share of clinical trial country-uses2021–202316%IQVIA2023actual→
Drug overdose deaths2025–202667,798CDCT12026estimate→
Drug overdose deaths year-over-year change2025–2026-12.3%CDCT12026estimate→
Fill rate for novel medicine prescriptions (first year)2020–202435%IQVIA2024actual→
Hospitals receiving Medicare IPPS payments2011–20123,000CMST12012actual→
Kindergarten vaccination coverage decline2025–20260.1%CDCT12026actual→
Lung cancer screening rate among eligible program members202454%CDCT12024actual→
Medicare IPPS discharge volume (top 100 DRGs)2011–20127,000,000CMST12012actual→
Medicare out-of-pocket cost decline rate20252.2%IQVIA2025actual→
Medicare out-of-pocket cost increase rate versus 20202020–202523%IQVIA2025actual→
Medicine market average annual growth at net prices (5-year)2021–20259.3%IQVIA2025actual→
Medicine spending growth forecast at list prices (high)2026–20309%IQVIA2030forecast→
Medicine spending growth forecast at list prices (low)2026–20306%IQVIA2030forecast→
Medicine spending growth forecast at net prices (high)2026–20307.5%IQVIA2030forecast→
Medicine spending growth forecast at net prices (low)2026–20304.5%IQVIA2030forecast→
National lung cancer screening rate202218%CDCT12022actual→
Net medicine spending growth rate +1 more 202510.6%IQVIA2025actual→
New medicine launches forecast (annual average, high)2026–203055IQVIA2030forecast→
New medicine launches forecast (annual average, low)2026–203050IQVIA2030forecast→
Non-retail share of medicine use202516%IQVIA2025actual→
Novel active substance launches +1 more 202553IQVIA2025actual→
Novel active substance launches, five-year total +1 more 2021–2025270IQVIA2025actual→
Novel medicines launched2020–202499IQVIA2024actual→
Oncology novel active substance (NAS) launches (cumulative)2020–202485IQVIA2024actual→
Patient organization-life sciences company deal value2008–20232.4 billion USDIQVIA2023estimate→
Patient organization-life sciences company deals2008–2023700IQVIA2023estimate→
Prescription medicine use growth20251.5%IQVIA2025actual→
Prescription medicine use growth (5-year)2021–202513%IQVIA2025actual→
Retail pharmacy prescription drug average annual growth (5-year)2021–20252.4%IQVIA2025actual→
Retail share of medicine use202584%IQVIA2025actual→
Rural Health Transformation Program state investment +4 more as of 15 Sep 2026104 million USDCMST12026actual→
Unfilled prescription rate (all brands and branded generics)end of 202529%IQVIA2025actual→
Unfilled rate for novel medicine prescriptions (first year)2020–202465%IQVIA2024actual→
Primary documents
Sources
| Document | Publisher | Authority tier | Published | Accessed | Locator | Data points |
|---|---|---|---|---|---|---|
| CDC Launches New Overdose Prevention Data Channel Press release | CDC | T1 Official | — | 16 Sep 2026 | RELEASE | 2 |
| CDC Statement on Newly Released Kindergarten Vaccination Data Press release | CDC | T1 Official | — | 16 Sep 2026 | STATEMENT | 1 |
| Twenty-Five Years After 9/11 Press release | CDC | T1 Official | — | 16 Sep 2026 | WTC Health Program lung cancer screening findings | 2 |
| Data Press release | CMS | T1 Official | — | 16 Sep 2026 | Medicare provider utilization & payment data: Inpatient Hospital Public Use File (PUF) | 2 |
| Newsroom Articles Press release | CMS | T1 Official | — | 16 Sep 2026 | Trump Administration Announces $104 Million to Transform Rural Healthcare Across Mississippi Through Cutting-Edge Technology and Expanded Care Closer to Home; Trump Administration Expands Preventive and Behavioral Healthcare Access for Students Across Rural North Carolina; Trump Administration Announces $11.7 Million to Expand Access, Improve Patient Care Facilities, and Strengthen Workforce Capacity in Nursing Homes and Long-Term Care System Across Rural Vermont | 5 |
| Supporting patients through research collaboration Press release | IQVIA | T3 Research | — | 16 Sep 2026 | Over the past 5 years patient organizations have received over 62.5 billion in revenue; Key findings | 5 |
| U.S. Medicine Use Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Other Findings; Key Findings | 23 |
| Rethinking Clinical Trial Country Prioritization Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Country utilization is heavily consolidated in U.S., China and Western European countries | 1 |
| Global R&D Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025 | 2 |
| Global R&D Trends 2026 Press release | IQVIA | T3 Research | — | 15 Sep 2026 | Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025 | 2 |
| Global Oncology Trends 2025 Press release | IQVIA | T3 Research | — | 16 Sep 2026 | Other Findings | 1 |
Report snapshots are retained internally for verification only and are never redistributed. Where a figure comes from a paywalled report, only the number published in its public summary is recorded.
All 46 collected records for United States are published as verified.
Cite & reuse
Cite this page
Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it. Each figure's own page carries APA, MLA, Chicago and BibTeX citations naming its original publisher.
StatOrigin. (2026). Healthcare in United States: statistics. Retrieved from https://statorigin.org/industries/healthcare/united-states